We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

China NMPA approves Innovent’s mazdutide, first dual GCG/GLP-1 receptor agonist for chronic weight management: San Francisco, US Monday, June 30, 2025, 12:00 Hrs [IST] Innovent ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon receptor (GCP) for obesity, observers are already making comparisons of the drug ...

A comprehensive review of nearly 150 studies reveals that coffee polyphenols may help regulate blood sugar and reduce ...